Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors

A prospective study

Ziad F. Bashshur, Ali Taher, Abdul Fattah Masri, Danny Najjar, Thurayya Arayssi, Baha' N. Noureddin

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Several reports have described the association between antiphospholipid antibodies (APAs) and retinal venous occlusive (RVO) disease. The purpose of this study was to look at the prevalence of these antibodies in patients with RVO disease and no conventional risk factors. We specifically examined how APAs may affect the course of this disease. Methods: Twenty-four patients with the diagnosis of RVO disease were screened prospectively for APAs. All were free from risk factors for retinal vein thrombosis and other immunologic conditions. Patients were observed for a period of 3 to 12 months. Results: Lupus anticoagulant was negative in all 24 patients. Ten (43%) of 24 patients had anticardiolipin antibodies (ACAs). All patients with ACAs were younger than 45 years of age, with an average age of 33 years. The average age of patients with no ACAs was 66 years. Comparison of the average age of the two groups showed a statistically significant difference. There was no statistical significance between the two groups for development of neovascular disease. Seropositive patients who developed neovascularization had elevated titers for an average of 11.8 weeks versus 3.3 weeks for those who did not have neovascularization. Neovascular complications generally began several weeks after the titers became negative. Conclusion: There was a significant prevalence of ACAs in young patients with RVO disease and no associated systemic risk factors. Seropositive patients who developed neovascular disease had elevated titers for more than 6 weeks. However, the role of these transient ACAs in retinal vein occlusion is still not clear and merits further study.

Original languageEnglish
Pages (from-to)486-490
Number of pages5
JournalRetina
Volume23
Issue number4
DOIs
Publication statusPublished - Aug 2003
Externally publishedYes

Fingerprint

Retinal Vein Occlusion
Anticardiolipin Antibodies
Prospective Studies
Antiphospholipid Antibodies
Lupus Coagulation Inhibitor
Age Groups

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors : A prospective study. / Bashshur, Ziad F.; Taher, Ali; Masri, Abdul Fattah; Najjar, Danny; Arayssi, Thurayya; Noureddin, Baha' N.

In: Retina, Vol. 23, No. 4, 08.2003, p. 486-490.

Research output: Contribution to journalArticle

Bashshur, Ziad F. ; Taher, Ali ; Masri, Abdul Fattah ; Najjar, Danny ; Arayssi, Thurayya ; Noureddin, Baha' N. / Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors : A prospective study. In: Retina. 2003 ; Vol. 23, No. 4. pp. 486-490.
@article{44dc99bfa32f492a806221791883f1f2,
title = "Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: A prospective study",
abstract = "Background: Several reports have described the association between antiphospholipid antibodies (APAs) and retinal venous occlusive (RVO) disease. The purpose of this study was to look at the prevalence of these antibodies in patients with RVO disease and no conventional risk factors. We specifically examined how APAs may affect the course of this disease. Methods: Twenty-four patients with the diagnosis of RVO disease were screened prospectively for APAs. All were free from risk factors for retinal vein thrombosis and other immunologic conditions. Patients were observed for a period of 3 to 12 months. Results: Lupus anticoagulant was negative in all 24 patients. Ten (43{\%}) of 24 patients had anticardiolipin antibodies (ACAs). All patients with ACAs were younger than 45 years of age, with an average age of 33 years. The average age of patients with no ACAs was 66 years. Comparison of the average age of the two groups showed a statistically significant difference. There was no statistical significance between the two groups for development of neovascular disease. Seropositive patients who developed neovascularization had elevated titers for an average of 11.8 weeks versus 3.3 weeks for those who did not have neovascularization. Neovascular complications generally began several weeks after the titers became negative. Conclusion: There was a significant prevalence of ACAs in young patients with RVO disease and no associated systemic risk factors. Seropositive patients who developed neovascular disease had elevated titers for more than 6 weeks. However, the role of these transient ACAs in retinal vein occlusion is still not clear and merits further study.",
author = "Bashshur, {Ziad F.} and Ali Taher and Masri, {Abdul Fattah} and Danny Najjar and Thurayya Arayssi and Noureddin, {Baha' N.}",
year = "2003",
month = "8",
doi = "10.1097/00006982-200308000-00007",
language = "English",
volume = "23",
pages = "486--490",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors

T2 - A prospective study

AU - Bashshur, Ziad F.

AU - Taher, Ali

AU - Masri, Abdul Fattah

AU - Najjar, Danny

AU - Arayssi, Thurayya

AU - Noureddin, Baha' N.

PY - 2003/8

Y1 - 2003/8

N2 - Background: Several reports have described the association between antiphospholipid antibodies (APAs) and retinal venous occlusive (RVO) disease. The purpose of this study was to look at the prevalence of these antibodies in patients with RVO disease and no conventional risk factors. We specifically examined how APAs may affect the course of this disease. Methods: Twenty-four patients with the diagnosis of RVO disease were screened prospectively for APAs. All were free from risk factors for retinal vein thrombosis and other immunologic conditions. Patients were observed for a period of 3 to 12 months. Results: Lupus anticoagulant was negative in all 24 patients. Ten (43%) of 24 patients had anticardiolipin antibodies (ACAs). All patients with ACAs were younger than 45 years of age, with an average age of 33 years. The average age of patients with no ACAs was 66 years. Comparison of the average age of the two groups showed a statistically significant difference. There was no statistical significance between the two groups for development of neovascular disease. Seropositive patients who developed neovascularization had elevated titers for an average of 11.8 weeks versus 3.3 weeks for those who did not have neovascularization. Neovascular complications generally began several weeks after the titers became negative. Conclusion: There was a significant prevalence of ACAs in young patients with RVO disease and no associated systemic risk factors. Seropositive patients who developed neovascular disease had elevated titers for more than 6 weeks. However, the role of these transient ACAs in retinal vein occlusion is still not clear and merits further study.

AB - Background: Several reports have described the association between antiphospholipid antibodies (APAs) and retinal venous occlusive (RVO) disease. The purpose of this study was to look at the prevalence of these antibodies in patients with RVO disease and no conventional risk factors. We specifically examined how APAs may affect the course of this disease. Methods: Twenty-four patients with the diagnosis of RVO disease were screened prospectively for APAs. All were free from risk factors for retinal vein thrombosis and other immunologic conditions. Patients were observed for a period of 3 to 12 months. Results: Lupus anticoagulant was negative in all 24 patients. Ten (43%) of 24 patients had anticardiolipin antibodies (ACAs). All patients with ACAs were younger than 45 years of age, with an average age of 33 years. The average age of patients with no ACAs was 66 years. Comparison of the average age of the two groups showed a statistically significant difference. There was no statistical significance between the two groups for development of neovascular disease. Seropositive patients who developed neovascularization had elevated titers for an average of 11.8 weeks versus 3.3 weeks for those who did not have neovascularization. Neovascular complications generally began several weeks after the titers became negative. Conclusion: There was a significant prevalence of ACAs in young patients with RVO disease and no associated systemic risk factors. Seropositive patients who developed neovascular disease had elevated titers for more than 6 weeks. However, the role of these transient ACAs in retinal vein occlusion is still not clear and merits further study.

UR - http://www.scopus.com/inward/record.url?scp=0041335446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041335446&partnerID=8YFLogxK

U2 - 10.1097/00006982-200308000-00007

DO - 10.1097/00006982-200308000-00007

M3 - Article

VL - 23

SP - 486

EP - 490

JO - Retina

JF - Retina

SN - 0275-004X

IS - 4

ER -